Market research
VXRT Vaxart Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 124M
- P/E ratio
- 3.0
- Analyst target
- 3.3333
- Dividend yield
- Not available
- Beta
- 1.07
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US92243A2006
- Market cap
- 124M
- P/E ratio
- 3.0
- Analyst target
- 3.3333
- Dividend yield
- Not available
- Beta
- 1.07
About
About Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. The company also provides VAAST (Vector-Adjuvant-Antigen Standardized Technology) Platform, a unique modular vaccine platform. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the VXRT discussion.
5 years, 4 months ago
Vaxart, Inc is currently in a long term uptrend where the price is trading 5.1% above its 200 day moving average.
From a valuation standpoint, the stock is 90.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 126.1.
Vaxart, Inc's total revenue sank by 99.9% to $4K since the same quarter in the previous year.
Its net income has increased by 100.0% to $-32 since the same quarter in the previous year.
Finally, its free cash flow fell by 206.7% to $-12M since the same quarter in the previous year.
Based on the above factors, Vaxart, Inc gets an overall score of 3/5.